Immunotherapy for B-cell neoplasms using T cells expressing chimeric antigen receptors from antigen choice to clinical implementation

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Immunotherapy with T cells expressing chimeric antigen receptors (CAR) is being evaluated as a potential treatment for B-cell neoplasms. In recent clinical trials it has shown promising results. As the number of potential candidate antigens expands, the choice of suitable target antigens becomes more challenging to design studies and to assess optimal efficacy of CAR. Careful evaluation of candidate target antigens is required to ensure that T cells expressing CAR will preferentially kill malignant cells with a minimal toxicity against normal tissues. B cells express specific surface antigens that can theoretically act as targets for CAR design. Although many of these antigens can stimulate effective cellular immune responses in vivo, their implementation in clinical settings remains a challenge. Only targeted B-cell antigens CD19 and CD20 have been tested in clinical trials. This article reviews exploitable B cell surface antigens for CAR design and examines obstacles that could interfere with the identification of potentially useful cellular targets.

Original languageEnglish
Pages (from-to)273-285
Number of pages13
JournalSultan Qaboos University Medical Journal
Volume12
Issue number3
Publication statusPublished - 2012

Fingerprint

Antigen Receptors
Immunotherapy
B-Lymphocytes
T-Lymphocytes
Antigens
Neoplasms
Surface Antigens
CD19 Antigens
Clinical Trials
Cellular Immunity

Keywords

  • B cells
  • Chimeric antigen receptors
  • Immunotherapy
  • Neoplasms
  • T cells

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{53f636d146e74c5ebc0d8a0496c69261,
title = "Immunotherapy for B-cell neoplasms using T cells expressing chimeric antigen receptors from antigen choice to clinical implementation",
abstract = "Immunotherapy with T cells expressing chimeric antigen receptors (CAR) is being evaluated as a potential treatment for B-cell neoplasms. In recent clinical trials it has shown promising results. As the number of potential candidate antigens expands, the choice of suitable target antigens becomes more challenging to design studies and to assess optimal efficacy of CAR. Careful evaluation of candidate target antigens is required to ensure that T cells expressing CAR will preferentially kill malignant cells with a minimal toxicity against normal tissues. B cells express specific surface antigens that can theoretically act as targets for CAR design. Although many of these antigens can stimulate effective cellular immune responses in vivo, their implementation in clinical settings remains a challenge. Only targeted B-cell antigens CD19 and CD20 have been tested in clinical trials. This article reviews exploitable B cell surface antigens for CAR design and examines obstacles that could interfere with the identification of potentially useful cellular targets.",
keywords = "B cells, Chimeric antigen receptors, Immunotherapy, Neoplasms, T cells",
author = "Boulassel, {Mohamed Rachid} and Ahmed Galal",
year = "2012",
language = "English",
volume = "12",
pages = "273--285",
journal = "Sultan Qaboos University Medical Journal",
issn = "2075-051X",
publisher = "Sultan Qaboos University",
number = "3",

}

TY - JOUR

T1 - Immunotherapy for B-cell neoplasms using T cells expressing chimeric antigen receptors from antigen choice to clinical implementation

AU - Boulassel, Mohamed Rachid

AU - Galal, Ahmed

PY - 2012

Y1 - 2012

N2 - Immunotherapy with T cells expressing chimeric antigen receptors (CAR) is being evaluated as a potential treatment for B-cell neoplasms. In recent clinical trials it has shown promising results. As the number of potential candidate antigens expands, the choice of suitable target antigens becomes more challenging to design studies and to assess optimal efficacy of CAR. Careful evaluation of candidate target antigens is required to ensure that T cells expressing CAR will preferentially kill malignant cells with a minimal toxicity against normal tissues. B cells express specific surface antigens that can theoretically act as targets for CAR design. Although many of these antigens can stimulate effective cellular immune responses in vivo, their implementation in clinical settings remains a challenge. Only targeted B-cell antigens CD19 and CD20 have been tested in clinical trials. This article reviews exploitable B cell surface antigens for CAR design and examines obstacles that could interfere with the identification of potentially useful cellular targets.

AB - Immunotherapy with T cells expressing chimeric antigen receptors (CAR) is being evaluated as a potential treatment for B-cell neoplasms. In recent clinical trials it has shown promising results. As the number of potential candidate antigens expands, the choice of suitable target antigens becomes more challenging to design studies and to assess optimal efficacy of CAR. Careful evaluation of candidate target antigens is required to ensure that T cells expressing CAR will preferentially kill malignant cells with a minimal toxicity against normal tissues. B cells express specific surface antigens that can theoretically act as targets for CAR design. Although many of these antigens can stimulate effective cellular immune responses in vivo, their implementation in clinical settings remains a challenge. Only targeted B-cell antigens CD19 and CD20 have been tested in clinical trials. This article reviews exploitable B cell surface antigens for CAR design and examines obstacles that could interfere with the identification of potentially useful cellular targets.

KW - B cells

KW - Chimeric antigen receptors

KW - Immunotherapy

KW - Neoplasms

KW - T cells

UR - http://www.scopus.com/inward/record.url?scp=84877835997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877835997&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:84877835997

VL - 12

SP - 273

EP - 285

JO - Sultan Qaboos University Medical Journal

JF - Sultan Qaboos University Medical Journal

SN - 2075-051X

IS - 3

ER -